Guidelines on Anaemia Management in Patients with Chronic Kidney Disease (CKD)
|
|
- Annice Mitchell
- 5 years ago
- Views:
Transcription
1 Guidelines on Anaemia Management in Patients with Chronic Kidney Disease (CKD) This guideline is for use in adult patients with an estimated Glomerular Filtration Rate (egfr) of less than 60ml/min/1.73m 2 and not on dialysis. It is intended for use by the Renal Department Multidisciplinary Team (MDT). Responsibilities for the management of anaemia in CKD The recognition and diagnosis of anaemia in patients with CKD is the responsibility of the patient s named consultant and other members of the renal medical team. Once the patient has been referred to the renal anaemia team, the team will be responsible for the on-going monitoring and treatment of anaemia, in consultation with the patients named consultant where necessary. The renal anaemia team will not be responsible for co-ordinating management if an appropriate referral is not received Anaemia medications in patients with CKD should only be prescribed by the renal consultants, trained renal middle grade doctors, trained renal specialist nurses or renal pharmacists. When to begin investigating and managing anaemia in CKD? a) Haemoglobin (Hb) falls to 110 g/l or less. or b) Symptoms attributable to anaemia such as tiredness, shortness of breath, lethargy and /or palpitation. 1 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
2 Consider causes for anaemia if Hb less than 110 g/l in CKD patients Low Mean Cell Volume (MCV) less than 80 femtolitres (fl) 1) Iron deficiency (e.g. Chronic gastrointestinal (GI) bleed) 2) Thalassemia Normal MCV 80 to 100 fl 1) Anaemia due to Chronic Disease (ACD) High MCV more than100 fl 1) B12/folate deficiency 2) Reticulocyosis e.g. secondary to haemolysis or acute GI bleed 3) Aplastic anaemia 4) Alcoholism with liver disease 5) Bone marrow pathology e.g. myelodysplastic syndromes, myeloid leukemia, myeloma 7) Azathioprine Note: 1) In cases of thalassemia, the MCV may be low even though the patient is not iron deficient. 2) High MCV may be seen in patients receiving Erythropoiesis Stimulating Agent (ESA). Baseline investigations All anaemic patients with CKD should have Hb, Percentage of Hypochromic Red blood cells (%HCR), Ferritin, B12, Folate, and Parathyroid Hormone (PTH) checked within 3 months at the time of presentation. As %HCR is not available in Leighton, Transferrin Saturation (TSAT) should be checked as an alternative marker. Treatment targets Target Hb: 100 to 120 g/l Target Ferritin: microgam/L Target %HRC less than 6% (unless ferritin is greater than 800 microgram/l) for Royal Stoke and County Patients Target TSAT more than 20% (unless ferritin is greater than 800 microgram/l) for Leighton patients 2 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
3 Interpretation of iron studies Functional Iron Deficiency Absolute Iron Deficiency Iron Replete Ferritin %HRC MCV TSAT (microgram/l) (RSUH + County) (fl) (Leighton) More than 100 More than 6% Less than 20% Less than 100 More than 6% Usually less than 80 Less than 20% More than 100 6% or below % or above Do not use Serum Ferritin or TSAT measurement alone to assess iron deficiency status. Absolute iron deficiency should prompt investigation and treatment. Functional iron deficiency with anaemia should be treated to ensure iron stores are replete. Treatment guidance Iron Replete Iron Deficiency Hb g/l Monitor Oral or IV iron as clinically indicated (please see below) Hb g/l ESA IV iron then ESA if Hb still less than 100 g/l Hb less than 90 g/l ESA IV iron and ESA 3 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
4 Choosing between oral and IV iron in CKD patients For patients with CKD (not on dialysis) who require iron replacement, consider a trial of oral iron as first line therapy. Offer IV iron therapy only if: Patient is intolerant of oral iron Patient is unresponsive to oral iron, i.e. target ferritin levels are not reached within 3 months Patient is on ESA therapy Ferric carboxymaltose (Ferinject ) dosage schedule Ferinject is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis of iron deficiency must be based on laboratory tests. The use of Ferinject is contraindicated in cases of: Hypersensitivity to the active substance, to Ferinject or any of its excipients (consult SPC) Known serious hypersensitivity (anaphylaxis) to other parenteral iron products Anaemia not attributed to iron deficiency, e.g. other microcytic anaemia Evidence of iron overload or disturbances in the utilisation of iron 4 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
5 If there is evidence of absolute or functional iron deficiency and ferritin is less than 500microgram/l please use table below: Hb Patient body weight g/l Less than 35 kg 35.1kg to 37.4kg 37.5kg to 49.9kg 50kg to 69.9kg Greater than 70 kg Less than mg Week 1: 700mg Week 2: 700mg Week 1: 750mg Week 2: 750mg Week 1: 1000mg Week 2: 500mg Week 1: 1000mg Week 2: 1000mg 100 to mg Week 1: 500mg Week 2: 500mg Week 1: 500mg Week 2: 500mg 1,000 mg Week 1: 1000mg Week 2: 500mg Greater than mg 500mg 500mg 500 mg 500 mg Ferinject should be diluted in 100mls sodium chloride 0.9% and given IV over 15 minutes via butterfly or venflon. Monitor patients carefully for signs and symptoms of hypersensitivity reactions during and following each administration of Ferinject. Hypersensitivity reactions can occur even when a previous administration has been tolerated. Caution is therefore needed with EVERY dose of IV iron, even if previous administrations have been well tolerated. Ferinject should only be administered when staff trained to evaluate and manage anaphylactic reactions is immediately available, in an environment where full resuscitation facilities can be assured. The patient should be observed for adverse effects for at least 30 minutes following each Ferinject injection. If any signs of a reaction- stop Ferinject, monitor vitals, ask for an urgent doctor s review. record details in CyberRen and Medisec, complete Medicines Health Regulatory Agency (MHRA) Yellow card & complete Trust Datix. Hypersensitivity reactions associated with Intravenous Iron products Cardiac Arrest The Medicines and Healthcare products Regulatory Agency (MHRA) have advised that intravenously administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic / anaphylactoid reactions. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes. The risk is enhanced for patients with known allergies including drug allergies, including patients with a history of severe asthma, eczema or other atopic allergy. There is also an increased risk of hypersensitivity reactions to intravenous iron complexes in patients with immune or inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis). 5 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
6 Ferinject should only be administered when staff trained to evaluate and manage anaphylactic reactions are immediately available, in an environment where full resuscitation facilities can be assured. If hypersensitivity reactions or signs of intolerance occur during administration, the treatment must be stopped immediately. Facilities for cardio respiratory resuscitation and equipment for handling acute anaphylactic / anaphylactoid reactions should be available, including an injectable 1:1000 adrenaline solution. Additional treatment with antihistamines and/or corticosteroids should be given as appropriate (see below). All patients need to be reviewed by a doctor in the event of anaphylactic reaction even if it was a mild reaction. For further information on acute anaphylaxis please consult UHNM Medical Guidelines Emergency medications used in case of anaphylactic reactions The following medicines must be prescribed for all patients receiving IV iron and only administered if an anaphylactic reaction is suspected: Adrenaline (1:1000) 500micrograms IM STAT (repeat after 5 minutes if required) Chlorphenamine 10 mg IV STAT (max 40mg in 24 hours) Hydrocortisone 200mg IM or slow IV STAT Contact cardiac arrest team (extension 2222) Test dose for intravenous Iron There are no clear data that an initial test dose minimizes risk of anaphylaxis: conversely, it may give false reassurance because hypersensitivity reactions have been reported in patients that had a negative initial test dose. Hence an initial test dose is not recommended. Infection The manufacturer cautions the use of IV Iron during an infective illness. The patient s consultant should be informed and IV iron should only be given if the patient s consultant judges that the benefits outweigh the risks. Other IV Iron should be used with caution in patients suffering from asthma, eczema or atopic allergies. Pregnancy There are no adequate and well-controlled trials of Ferinject in pregnant women. A careful benefit/risk evaluation is required before use during pregnancy and Ferinject should not be used during pregnancy unless clearly necessary. Iron deficiency occurring in the first trimester of pregnancy can in many cases be treated with oral iron. Treatment with Ferinject should be confined to the second and third trimester if the benefit is judged to outweigh the potential risk for both the mother and the foetus. 6 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
7 Animal data suggest that iron released from Ferinject can cross the placental barrier and that its use during pregnancy may influence skeletal development in the fetus. Breast-feeding Clinical studies showed that transfer of iron from Ferinject to human milk was negligible ( 1%). Based on limited data on breast-feeding women it is unlikely that Ferinject represents a risk to the breast-fed child. Fertility There are no data on the effect of Ferinject on human fertility. Fertility was unaffected following Ferinject treatment in animal studies. Reassessment of anaemia parameters following IV iron infusion The Hb level should be re-assessed by the renal anaemia team no earlier than 4 weeks following final Ferinject administration to allow adequate time for erythropoiesis and iron utilisation. In the event the patient requires further iron, the iron need should be recalculated using the dosing table (see page 5). Repeat Hb, ferritin, and %HRC in 4-6 weeks after IV Ferinject load. Note TSAT will be measured for Leighton patients only (in lieu of %HRC). Repeat further course if there is evidence of absolute or functional iron deficiency and ferritin is less than 500microgram/l (see interpretation of iron study table on page 3) Repeat iron indices 3 monthly. 7 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
8 Erythropoiesis Stimulating Agent (ESA) ESA should be offered to people with anaemia of CKD who are likely to benefit in terms of quality of life and physical function. Measurement of erythropoietin levels should not be routinely considered for diagnosis in CKD with anaemia. ESA should only be initiated after correcting Iron, B12 and folate deficiency. ESA treatment responsibilities: ESA must be prescribed by the renal team (e.g. renal consultants, trained renal middle grade doctors, trained renal specialist nurses or renal pharmacists). Home delivery is arranged by the CKD team, who will also be responsible for training patients/carers to administer ESA. It is the responsibility of the renal anaemia specialist nurse, in consultation with the patient s named consultant, to monitor response to treatment and adjust dosing. The patient s General Practitioner (GP) must be informed on initiation of therapy and it must be communicated that they will not be responsible for prescribing / supplying ESA therapy. It is departmental policy that the patient / carer will administer ESA treatment. If this is not possible, and in exceptional circumstances, the patient s GP practice or local District Nurse services may be asked to administer ESA therapy. However the department acknowledges that the patient s GP practice or local District Nurse services do not have an obligation to help with administration and if they decline to do so the patient will need to have treatment on the Kidney Unit. Treatment with ESA should be patient centred. After referral to the CKD anaemia team each patient will be contacted by a renal anaemia specialist nurse and given: Information about how ESA works, its benefits and side effects A plan for drug supply and administration Instructions for monitoring blood pressure and acceptable parameters Regular blood tests and reviews Awareness of the importance of concordance with therapy 8 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
9 ESA preparation The Renal Department at UHNM is currently using Darbepoetin alfa (Aranesp ). This reflects ESA choice on the North Staffordshire Joint Formulary. Darbepoetin alfa is available in two forms: pre-filled syringes and sure-click injection. However the Renal Department at UHNM recommends using the pre-filled syringe device and the dosing recommendations in this guideline reflects this. Dose of darbepoetin alfa Weight Range (kg) Dose Frequency micrograms Fortnightly micrograms Fortnightly micrograms Fortnightly micrograms Fortnightly micrograms Fortnightly For dosing patients less than 35kg or more than 100kg discuss with their named consultant This dosing strategy is for darbepoetin alfa prefilled syringes which are available in 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300 and 500micrograms. Blood Pressure ESA treatment may result in a rapid rise in, and very high absolute levels of, blood pressure. This could result in hypertensive encephalopathy. Therefore careful monitoring of blood pressure is essential during treatment. Check blood pressure before every darbepoetin alfa (ESA) administration. If blood pressure is greater than 160/90mmHg suspend ESA and restart only when blood pressure controlled. If blood pressure rises on ESA this should be controlled with antihypertensive medication. 9 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
10 Pregnancy There are no adequate and well-controlled studies with darbepoetin alfa in pregnant women. Animal studies do not indicate direct harmful effects with respect to pregnancy, embryonal/ foetal development, parturition or postnatal development. No alteration of fertility was detected. Caution should be exercised when prescribing darbepoetin to pregnant women. Amgen no longer have a pregnancy surveillance programme. Pregnancy is monitored as part of the normal surveillance programme. Women who become pregnant can contact Amgen Medical Information via Amgen safety will conduct a normal follow-up (a data collection form during pregnancy, one post-delivery and short update forms at 6 & 12 months these forms will be sent to the patient). Breast-feeding It is unknown whether darbepoetin is excreted in human milk. A risk to the breast-feeding child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue / abstain from darbepoetin therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. Monitoring bloods on ESA - darbepoetin alfa Induction Phase of ESA. Monitor the following every 4 weeks: - FBC Ferritin U&E % HRC (RSUH + County) TSAT (for Leighton patients) Maintenance Phase of ESA. Continue to monitor the above every 8 weeks. This monitoring will be coordinated by the renal anaemia team, with input from the patient s named consultant when necessary. 10 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
11 Summary of initial management of anaemia in CKD patients Hb less than 110 g/l or symptoms attributable to renal anaemia Ferritin less than 500 mcg/l Correct B12 and Folate deficiency YES NO Ferritin less than 200 mcg/l YES NO Ferritin 200 to 500 mcg/l HRC more than 6% TSAT less than 20% YES Functional Iron deficiency NO Monitor Hb and consider ESA if Hb drops below 100 g/l Is Hb more than 90 g/l but less than 110 g/l Yes Iron therapy (po/iv as appropriate) No Assess Hb at 4-6 weeks Hb less than 90 g/l ESA & Iron If Hb increase less than 10g/l after 4 week, Increase ESA as per dose adjustment table (page 9) Hb more than 105 g/l Monitor Hb less than 105 g/l 11 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar ESA Maintain Hb 105 to 115 g/l
12 Dose adjustment of ESA - darbepoetin alfa The renal anaemia team will maintain the aspirational Hb range between 100 and 120 g/l for adults (unless a different aspirational range has been agreed with the patient s named consultant). Do not wait until Hb levels are outside the aspirational range before adjusting treatment (consider adjusting ESA dose if Hb level falls less than 105 and more than 115 g/l). ESA adjustment schedule for adult patients make adjustments based on absolute Hb level and / or rate of change of Hb more than 10 g/l/month To utilise patients darbepoetin stock, initially consider either increasing dose frequency for doses that need to be increased or decreasing dose frequency (minimum monthly) for doses that need to be decreased, before changing dose. Current Dose (microgram/fortnight) Increased Dose (microgram/fortnight) Decreased Dose (microgram/fortnight) Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
13 Maintenance algorithm for CKD patients on ESA + IV iron Monitor Ferritin, % HRC (RSUH + County) or TSAT (Leighton patients) every 8 weeks Maintain serum ferritin level between 200 microgram/l and 500 microgram/l %HRC less than 6% (unless ferritin is greater than 800 microgram/l) TSAT more than 20% (Leighton patients) Measure Hb Hb less than105g/l Hb 105 to 115g/L Hb 115 to 125 g/l Hb more than130 g/l Increase ESA dose as per dose adjustment table (page 12) No change unless Hb rising by more than g /L/month Consider reducing ESA dose and / or frequency by 25% as per dose adjustment table (page 12) Stop ESA and Check Hb fortnightly. When Hb drops below 115g/L restart ESA at a dose approximately 25% lower than the previous dose (page 12) 13 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
14 Individualising the aspirational range There are times when it is appropriate to individualise the aspirational range for Hb. Consider individualising the aspirational range for example for physically inactive patients and patients with physically demanding job / lifestyle. This should be a consultant decision. If deciding to maintain Hb outside the aspirational range, the risks and benefits should be discussed with the patient and documented in clinical notes When to suspect ESA resistance NICE states this should be suspected when anaemia is not corrected despite a dose equivalent to greater than 1.5micrograms/kg/week of darbepoetin alfa. There is continued need for administration of high doses of ESAs to maintain the aspirational range. 1) Iron deficiency 2) Chronic blood loss 3) Intercurrent illness such as Infections and inflammations 4) Vitamin deficiencies (eg: Folate & vitamin B12 deficiency) 5) Hyperparathyroidism 6) Bone Marrow pathology e.g. multiple myeloma, myelodysplasia 7) Other malignancy 8) Hemoglobinopathies (eg: Thalassemia, Sickle cell) 9) Malnutrition 10) Aluminium Toxicity Main conditions associated with ESA resistance 14 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
15 Criteria for escalation to patient s named consultant ESA resistance is suspected There is any suspicion of infection / sepsis Newly diagnosed cancer The decision to use ESA should be based on an assessment of the benefits and risks for individual patients. Blood Pressure is greater than 160/90 mmhg while on ESA. If patient is pregnant or breast feeding. Suspected pure red cell aplasia (PRCA) This should be suspected if Hb decreases by 1g/L/day, corresponding to the life span of red cells, in absence of GI blood loss in patients with or without ESA resistance. As iron use is largely abolished in PRCA as a result of absence of marrow erythropoietic activity. Therefore, ferritin levels are very high with a very low reticulocyte count. Guideline disclaimer Aranesp Please note this clinical guideline is expected to cover the anaemia management of the majority of patients with CKD. It is estimated that it will provide clinically appropriate options for 80% of patients. All patient are individuals, however, and it is recognised that there will be some situations where prescribing outside of theses clinical guidelines may be necessary. Please note these guidelines have been created using information within NICE Clinical Guideline NG8, CKD: managing anaemia (June 2015) with adaptations in line with local policy, as agreed by the UHNM Renal Department. 15 Reviewed by Dr A McClean, CKD Nursing Team, Kate Webb & Imran Anwar
GUIDELINES FOR ADMINISTRATION OF INTRAVENOUS IRON IN ADULTS WITH CHRONIC KIDNEY DISEASE
GUIDELINES FOR ADMINISTRATION OF INTRAVENOUS IRON IN ADULTS WITH CHRONIC KIDNEY DISEASE Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 2-year surveillance (2017) Chronic kidney disease: managing anaemia (2015) NICE guideline NG8 Appendix A3: Summary of new evidence from surveillance Diagnostic
More informationEFFECTIVE SHARE CARE AGREEMENT
Specialist details Patient identifier Name: Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of Erythropoietin Stimulating Agent (ESA) Therapy (formerly known as EPO) for the correction of Anaemia
More informationSummary of Recommendation Statements Kidney International Supplements (2012) 2, ; doi: /kisup
http://www.kidney-international.org & 2012 KDIGO Summary of Recommendation Statements Kidney International Supplements (2012) 2, 283 287; doi:10.1038/kisup.2012.41 Chapter 1: Diagnosis and evaluation of
More informationUniversity Hospitals Coventry & Warwickshire NHS Trust
University Hospitals Coventry & Warwickshire NHS Trust Clinical Guideline (full) Anaemia management for chronic kidney disease, peritoneal dialysis, renal transplant and haemodialysis patients E-Library
More informationCAUTION: You must refer to the intranet for the most recent version of this procedural document.
Procedure for the use of Intravenous Iron Dextran (CosmoFer ) Sharepoint Location Sharepoint Index Directory Clinical Policies and Guidelines General Policies and Guidelines/ Haematology And blood transfusion
More informationPREOPERATIVE ANAEMIA PATHWAY
PREOPERATIVE ANAEMIA PATHWAY Surname: Patient ID No. Forename: DOB: / / Age: NHS Number: Likes to be called: Address: Tel. No. Religion/Spirituality: Next of Kin: Name GP Name: GP Practice: Planned Operation:
More informationMIRCERA. INN: Methoxy polyethylene glycol-epoetin beta. Pre-filled syringe. Composition
MIRCERA INN: Methoxy polyethylene glycol-epoetin beta Pre-filled syringe Composition Single dose pre-filled syringes: containing 50µg, 75µg, 100µg, 150µg, 200µg, or 250µg methoxy polyethylene glycol-epoetin
More informationNICE guideline Published: 3 June 2015 nice.org.uk/guidance/ng8
Chronic kidney disease: managing anaemia NICE guideline Published: 3 June 2015 nice.org.uk/guidance/ng8 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationNURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL
CANN-NET ANEMIA MANAGEMENT FOR HEMODIALYSIS CENTRES NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL TABLE OF CONTENTS: Hemoglobin Status Assessment ------------------------------------------- Page 1
More informationBeaumont Hospital Department of Transplantation, Urology and Nephrology. Guideline for administering Intravenous Ferinject in the Renal Unit
Beaumont Hospital Department of Transplantation, Urology and Nephrology Guideline for administering Intravenous Ferinject in the Renal Unit Document Number: 18 Reason for Change Review and update Original
More informationTrust Guideline for the Management and Administration of Intravenous Iron in Adults under the Gastroenterology Directorate
A clinical guideline recommended for use For Use in: The Gastroenterology Directorate By: Registered nurses competent in the administration of intravenous therapy and medical staff For: Adult patients
More informationiron III isomaltoside 1000 (contains 50mg iron per ml) (Diafer ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited
Re-submission iron III isomaltoside 1000 (contains 50mg iron per ml) (Diafer ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited 13 January 2017 The Scottish Medicines Consortium (SMC)
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationRenal association clinical practice guideline on Anaemia of Chronic Kidney Disease
Mikhail et al. BMC Nephrology (2017) 18:345 DOI 10.1186/s12882-017-0688-1 CORRESPONDENCE Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease Ashraf Mikhail 1*, Christopher
More informationPolicy for the use of intravenous Iron Dextran (CosmoFer )
Policy for the use of intravenous Iron Dextran (CosmoFer ) Sharepoint Location Clinical Policies and Guidelines Sharepoint Index Directory General Policies and Guidelines Sub Area Haematology and Blood
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationIn-House. Solution for Injection A dark brown coloured, slightly viscous solution filled in ampoule.
Iron Sucrose Injection USP 20 mg/ml Iron sucrose Eq. to Elemental Iron 01 Iron sucrose Eq. to Elemental Iron In-House 02 Sodium Hydroxide BP 333.0 Eq. to 20.00 Q.S. to adjust ph Iron supplement ph Adjustment
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd
Resubmission ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd 06 May 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationManaging peri-operative anaemiathe Papworth way. Dr Andrew A Klein Royal Papworth Hospital Cambridge UK
Managing peri-operative anaemiathe Papworth way Dr Andrew A Klein Royal Papworth Hospital Cambridge UK Conflicts of interest: Unrestricted educational grants/honoraria from CSL Behring, Brightwake Ltd,
More informationDr Charlie Baker Consultant Anaesthetist UHNM. Being a place our f amilies would choose
Dr Charlie Baker Consultant Anaesthetist UHNM Being a place our f amilies would choose The story so far: Anaemia is associated with transfusion. The more anaemic you are pre op the more likely you are
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin zeta, 1000 IU/0.3ml, 2000 IU/0.6ml, 3000 IU/0.9ml, 4000 IU/0.4ml, 5000 IU/0.5ml, 6000 IU/0.6ml, 8000 IU/0.8ml, 10,000 IU/1.0ml, 20,000 IU/0.5ml, 30,000 IU/0.75ml and
More informationNational Comparative Audit of red cell transfusion in Medical Patients Part Two
National Comparative Audit of red cell transfusion in Medical Patients Part Two Dr. Kate Pendry, Project Clinical Lead John Grant-Casey, Project Manager August 2013 Part One 9216 cases from 181 sites (90%
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationA treatment to fit your needs
A treatment to fit your needs Aranesp (darbepoetin alfa) is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on
More informationSummary of Product Characteristics
Summary of Product Characteristics This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report
More informationAzathioprine Shared Care Guideline for GPs
Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More information27/01/2019. Anaemia, Transfusion and TACO Lise Estcourt. Anaemia. What is anaemia?
Anaemia, Transfusion and TACO Lise Estcourt 1 Anaemia 2 What is anaemia? 3 1 Anaemia according to WHO 4 Anaemia in palliative care Common (77% men 68% women) Symptoms often non-specific Some causes potentially
More informationVenofer 20 mg iron / ml, solution for injection or concentrate for solution for infusion.
SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report
More informationROYAL WOLVERHAMPTON HOSPITALS NHS TRUST
ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST SHARED CARE PROTOCOL FOR ERYTHROPOIETIN USE 2016 New Cross Hospital Dr J Odum Dr P B Rylance Dr P Carmichael Dr S Acton Dr B Ramakrishna Walsall Manor Hospital Dr
More informationNURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL EDUCATIONAL PACKAGE TABLE OF CONTENTS:
CANN-NET ANEMIA MANAGEMENT FOR HEMODIALYSIS CENTRES NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT TABLE OF CONTENTS: PROTOCOL EDUCATIONAL PACKAGE Page 2: CANN-NET Anemia Management Protocol: Educational Document
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin theta, 1,000 IU/0.5mL, 2,000 IU/0.5mL, 3,000 IU/0.5mL, 4,000 IU/0.5mL, 5,000 IU/0.5mL, 10,000 IU/1mL, 20,000 IU/1mL, 30,000 IU/1mL solution for injection in pre filled
More informationClinical Policy: Darbepoetin alfa (Aranesp) Reference Number: ERX.SPMN.13
Clinical Policy: (Aranesp) Reference Number: ERX.SPMN.13 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationManagement of Anaemia
Management of Anaemia Janet Birchall Consultant Haematologist North Bristol Trust and NHS Blood & Transplant Case History - DW age 86 years 14.30 FBC by GP Hb 58 g/l, ferritin 3microg/L. Hospital review
More informationIRON DEFICIENCY / ANAEMIA ANTHONY BEETON
IRON DEFICIENCY / ANAEMIA ANTHONY BEETON HYPOXIA 1-2 mg IRON Labile iron Body iron ± 3 4 g Liver and the reticuloendothelial system and spleen (approximately 200 300 mg in adult women and 1 g in adult
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationHYDROXYCARBAMIDE for Haematological conditions (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological
More informationIron treatment for people with chronic kidney disease (CKD)
Iron treatment for people with chronic kidney disease (CKD) Information for patients Oxford Kidney Unit If you have chronic kidney disease or are receiving peritoneal dialysis (PD) or hospital dialysis
More informationIntravenous ferric carboxymaltose:
HAEMATOLOGY Medicine subsidy Medicine indications Intravenous ferric carboxymaltose: now available for the treatment of iron deficiency Key practice points: Ferric carboxymaltose is an intravenous iron
More informationPackage Insert. Product Summary. 1. Name of the medicinal product
Package Insert Raricap S Inj Product Summary 1. Name of the medicinal product Raricap S Inj 2. Qualitative and quantitative composition Each1 ml contains: Ferric hydroxide in complex with sucrose equivalent
More informationNorthern Treatment Advisory Group
Northern Treatment Advisory Group Ferric Maltol (Feraccru ) for the treatment of iron deficiency Lead author: Daniel Hill Regional Drug & Therapeutics Centre (Newcastle) September 2018 2018 Summary Iron
More informationEssential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community
E088 Essential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community Patient s name: DOB NHS Number Patient s address: Consultant Note: Shared care agreement sets out a
More informationPREOPERATIVE ANAEMIA PATHWAY
PREOPERATIVE ANAEMIA PATHWAY Surname: Unit No. Forename: DOB: / / Age: NHS Number: Likes to be called: Address: Tel. No. Religion/Spirituality: GP Name: GP Practice: Planned Operation: Postcode: Mobile
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationLaboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth
Laboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth Why does it matter? Over 30% of the Worlds population are anaemic,
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationUniversity Hospitals of Leicester NHS Trust ANAEMIA_IRON THERAPY FOR ANAEMIA OF CHRONIC KIDNEY DISEASE. RRCV CMG Nephrology Service
1. Introduction Anaemia is a common complication of chronic kidney disease with the prevalence of anaemia increasing as glomerular filtration rate falls. The management of anaemia in CKD for both non-dialysis
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationMedicines Formulary Blood and electrolyte disorders, and vitamin deficiencies
Medicines Formulary Blood and electrolyte disorders, and vitamin deficiencies Contents: Blood disorders 1 1. Anaemia 2 A. Non-renal patients 2 B. Patients with chronic kidney disease under the care of
More informationNORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Azathioprine Treatment of rheumatological conditions
More informationAlister Jones Patient Blood Management Practitioner NHS Blood and Transplant
Alister Jones Patient Blood Management Practitioner NHS Blood and Transplant All medical RCC transfusions (but only 1 in 3 haematology or oncology cases) in 3 x one week periods Medical specialties include:
More informationPre-operative Anaemia Colorectal and Orthopaedic Surgery
Pre-operative Anaemia Colorectal and Orthopaedic Surgery Dr Simon Rang Consultant Anaesthetist East Kent Hospitals NHS Trust Dreamland Pre-operative Anaemia Anaemia is a perioperative risk factor Perioperative
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.
ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. Specialist details Patient identifier Name Tel: This effective shared care agreement (ESCA) sets out details for the sharing of
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Epoetin alfa HEXAL 1,000 IU/0.5 ml solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2,000 IU/1 ml solution
More informationMonofer Prescribing and Administration Guideline
Maternity Intravenous Iron Infusion Monofer Prescribing and Administration Guideline The purpose of this guideline is to advise medical and nursing staff on the safe prescribing and administration of Monofer.
More informationAn Audit of Poor Response To Erythropoeitin Therapy. September 1998
1 An Audit of Poor Response To Erythropoeitin Therapy September 1998 Prepared By: Nicola Austerberry Renal Audit Facilitator Phil Kalra Consultant Nephrologist 2 1 Introduction The topic for this audit
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRIFERIC safely and effectively. See full prescribing information for TRIFERIC. TRIFERIC (ferric
More informationRenal anaemia. Information for you. Follow us on Find us on Facebook at Visit our website:
Renal anaemia Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net All our publications are available in other formats This
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Addaven concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Addaven contains: 1 ml 1 ampoule (10 ml) Chromic
More informationUpdate on the management of iron deficiency
Update on the management of iron deficiency Outline Need to improve management & avoid transfusion Diagnosis & investigation Oral iron & IV iron Tools & resources No conflicts of interest All natural
More informationNZBS HAEMOCHROMATOSIS & THERAPEUTIC VENESECTION POLICY
REASON FOR ISSUE: New Document for TV Clinic 1. INTRODUCTION NZBS will provide a venesection service for people in New Zealand who require venesection for conditions that are known to benefit from therapeutic
More informationSummary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s)
http://www.kidney-international.org & 2012 International Society of Nephrology Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s) Tilman B. Drüeke 1 and Patrick S.
More informationDimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients
Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients Author and Contact details: Responsible Director: Ian Pomeroy Service lead for MS. Tel: (0151) 529 5715 Email: ian.pomeroy@thewaltoncentre.nhs.uk
More informationKidney damage with normal or increased GFR Kidney damage with mild reduction in GFR
CHRONIC KIDNEY DISEASE Contents Stages of Chronic Kidney Disease Dosing adjustments Hyperphosphataemia management Secondary hyperparathyroidism Anaemias Hyperkalaemia Acidosis Hypertension STAGES OF CHRONIC
More informationProtocol for Ferric Carboxymaltose (Ferinject ) Injection Use in Paediatric Services
Procol for Ferric Carboxymalse (Ferinject ) Injection Use in Paediatric Services Specialty: Paediatric Services Date Approved: 19 th March 2014 Approved by: W&CH Quality & Safety Group Date for Review:
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More information1 INDICATIONS AND USAGE. 1.1 Limitation of Use FULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRIFERIC safely and effectively. See full prescribing information for TRIFERIC. TRIFERIC (ferric
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Darbepoetin Alfa (Aranesp) Reference Number: CP.PHAR.236 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important
More informationFactsheet Sacubitril valsartan (Entresto ) for chronic heart failure with reduced ejection fraction
North Central London Joint Formulary Committee Factsheet Sacubitril valsartan (Entresto ) for chronic heart failure with reduced ejection fraction Start date: July 2016 Review date: July 2019 Document
More informationFactsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C)
North Central London Joint Formulary Committee Factsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C) Start date: September 2018 Review date: September 2021 Document
More informationAdvanced Level. Understanding Iron Deficiency Anaemia in Chronic Kidney Disease Information at Advanced Level. Karen Jenkins RN, PGDip HE, MSc
Advanced Level European Dialysis and Transplant Nurses Association/ European Renal Care Association Understanding Iron Deficiency Anaemia in Chronic Kidney Disease Information at Advanced Level. Karen
More informationPATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )
PATIENT GROUP DIRECTION Administration of: Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) By: Practice Nurses In: General Practice It is the responsibility of the professional working under
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationDETECTION, INVESTIGATION AND MANAGEMENT OF ANAEMIA
From the Chief Medical Officer Dr Michael McBride HSS(MD) 22/2012 Circulation list: For Action: Chief Executives of HSC Trusts Medical Directors of HSC Trusts (for onward distribution to All Hospital Doctors)
More informationRENAL ANAEMIA. South West Renal Training Scheme Cardiff October 2018
RENAL ANAEMIA South West Renal Training Scheme Cardiff October 2018 Dr Soma Meran Clinical Senior Lecturer and Honorary Consultant Nephrologist, University Hospital of Wales. Aims Biology of renal anaemia
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More informationAnaemia management in people with chronic kidney disease (partial update)
Anaemia management in people with chronic kidney disease (partial update) NICE guideline Draft for consultation, October 2010 If you wish to comment on this version of the guideline, please be aware that
More informationCosmoFer. Dose Selection and Calculation Guide for intravenous administration. Low molecular weight iron dextran. Revised TDI tables
CosmoFer Low molecular weight iron dextran Dose Selection and Calculation Guide for intravenous administration Revised TDI tables low Mw iron dextran Before prescribing CosmoFer please refer to full local
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Methoxy polyethylene glycol-epoetin beta (Mircera) Reference Number: CP.CPA.322 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 November 2010 Examination of the dossier of the proprietary medicinal product included on the list for a limited
More informationErythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) (Subcutaneous/Intravenous) *NON DIALYSIS* Document Number: IC 0242
Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) (Subcutaneous/Intravenous) *NON DIALYSIS* Document Number: IC 0242 Last Review Date: 05/01/2018 Date of Origin: 10/17/2008 Dates Reviewed:
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationPatient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationDeveloped By Name Signature Date
Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:
More informationKELFER Deferiprone. COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg
KELFER Deferiprone COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg DOSAGE FORM Capsules PHARMACOLOGY Pharmacodynamics
More informationAPOMORPHINE (Adults) Shared Care Guidelines DRUG:
Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.
More information